ASCO 2023 | EV-103: EV with pembrolizumab in cisplatin-ineligible urothelial carcinoma

Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, describes the rationale and trial design of the EV-103 trial (NCT03288545), which assessed enfortumab vedotin (EV), an antibody-drug conjugate (ACD), and pembrolizumab in patients with first-line cisplatin-ineligible locally advanced or metastatic urothelial carcinoma. The combination of EV and pembrolizumab had encouraging antitumor activity and a manageable safety profile in cohort A, which had a dose escalation component, and cohort K. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.